Table 2 Seropositivity to individual sexually transmitted infections and risk of ovarian cancer: results from the NHS and NHSII
Control, n | All cases | Borderline ovarian tumours | Invasive EOC | Invasive serous EOC | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unadjusted | Adjusteda | Adjusteda | Adjusteda | Adjusteda | |||||||||||
Case, n | RR | 95% CI | RR | 95% CI | Case, n | RR | 95% CI | Case, n | RR | 95% CI | Case, n | RR | 95% CI | ||
C. trachomatis | |||||||||||||||
Negative | 297 | 271 | Ref. | Ref. | 63 | Ref. | 208 | Ref. | 135 | Ref. | |||||
Positive | 40 | 66 | 2.04 | 1.26–3.29 | 2.07 | 1.25–3.43 | 17 | 2.11 | 1.04–4.28 | 49 | 1.98 | 1.21–3.23 | 35 | 2.31 | 1.33–4.01 |
M. genitalium | |||||||||||||||
Negative | 328 | 320 | Ref. | Ref. | 74 | Ref. | 246 | Ref. | 164 | Ref. | |||||
Positive | 9 | 17 | 2.00 | 0.86–4.67 | 1.92 | 0.78–4.72 | 6 | 2.75 | 0.86–8.76 | 11 | 1.81 | 0.68–4.77 | 6 | 1.59 | 0.51–4.98 |
Herpes simplex virus, type 2 | |||||||||||||||
Negative | 308 | 299 | Ref. | Ref. | 68 | Ref. | 231 | Ref. | 152 | Ref. | |||||
Positive | 29 | 38 | 1.36 | 0.81–2.28 | 1.38 | 0.79–2.42 | 12 | 2.04 | 0.92–4.54 | 26 | 1.24 | 0.69–2.26 | 18 | 1.32 | 0.68–2.59 |
HPV16 E6 or HPV18 E6+E7 or HPV45 E6+E7 | |||||||||||||||
Negative | 330 | 326 | Ref. | Ref. | 77 | Ref. | 249 | Ref. | 164 | Ref. | |||||
Positive | 7 | 11 | 1.57 | 0.61–4.05 | 1.23 | 0.44–3.44 | 3 | 2.03 | 0.47–8.77 | 8 | 1.37 | 0.47–3.99 | 6 | 1.84 | 0.58–5.88 |